D06 Carcinoma in situ of cervix uteri

Name of the Condition

• Carcinoma in situ of cervix uteri
• Also known as Cervical intraepithelial neoplasia grade III (CIN III).

Summary

Carcinoma in situ of the cervix uteri is a precancerous condition where abnormal cells are confined to the surface layer of the cervix. At this stage, the cells have not invaded deeper tissues or spread to other parts of the body.

Causes

The primary cause is persistent infection with high-risk types of human papillomavirus (HPV), particularly types 16 and 18.

Risk Factors

• Persistent HPV infection, early onset of sexual activity, multiple sexual partners, smoking, and a weakened immune system.

Symptoms

• Often asymptomatic, but possible signs include abnormal vaginal bleeding, discharge, or pelvic pain.

Diagnosis

Primarily through a Pap smear and HPV testing. Confirmed with a colposcopy and a biopsy of cervical cells.

Treatment Options

• Conservative Management: Active monitoring for mild cases.
• Surgical Procedures: Loop electrosurgical excision procedure (LEEP), cold knife cone biopsy, or laser surgery to remove abnormal cells.
• How it Helps: These treatments aim to prevent the progression to invasive cervical cancer by removing the affected tissue.

Prognosis and Follow-Up

With appropriate treatment, the prognosis is excellent with a high cure rate. Regular follow-ups with Pap tests are crucial to monitor for recurrence.

Complications

• If left untreated, carcinoma in situ may progress to invasive cervical cancer, which can spread to surrounding tissues and other organs.

Lifestyle & Prevention

• Regular cervical screening (Pap tests) to detect abnormalities early.
• HPV vaccination to reduce infection risk.
• Avoid smoking and practice safe sexual behaviors to lower HPV exposure.

When to Seek Professional Help

• Abnormal vaginal bleeding, persistent discharge, or pelvic pain.
• Positive results from routine cervical screening tests.

Tips for Medical Coders

• Code D06 is used for carcinoma in situ of the cervix uteri. Documentation should specify the location (e.g., endocervix, exocervix) if available, as this may impact coding specificity. Ensure the diagnosis aligns with histopathological confirmation of in situ changes without invasion.